Table 3.
Phase III Trials of First-Line Immunotherapy-Based Combination Therapies
| Trial (Year of Report) | Experimental Arm | Control Arm | mPFS (HR, 95% CI) (Months) | mOS (HR, 95% CI) (Months) |
|---|---|---|---|---|
| Checkmate 21461 (2018) | Ipilimumab plus nivolumab | Sunitinib | 12.4 vs 12.3 (0.98, 0.79–1.23) | NR vs 32.9 (0.68, 0.49–0.95) |
| IMmotion15168 (2019) | Atezolizumab plus bevacizumab | Sunitinib | 11.2 vs 8.4 (0.83, 0.70–0.97) | 33.6 (29.0–NE) vs 34.9 (27.8–NE); (0.93, 0.76–1.14) |
| JAVELIN Renal 10166 (2019) | Avelumab plus axitinib | Sunitinib | 13.8 vs 8.4 (0.69, 0.57–0.84) | (0.78, 0.55–1.08) |
| KEYNOTE-426 (2019) | Pembrolizumab plus axitinib | Sunitinib | 15.1 vs 11.1 (0.69, 0.57–0.84) | (0.53, 0.38–0.74) |
Abbreviations: mPFS, median progression-free survival; HR, hazard ratio; CI, confidence interval; mOS, median overall survival; NR, not reached; NE, not estimable.